SPI-2012 vs Pegfilgrastim in Management of Neutropenia in BReast Cancer Patients With Docetaxel and Cyclophosphamide
Status:
Completed
Trial end date:
2019-07-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of SPI-2012 with pegfilgrastim in
patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) to
prevent and reduce Neutropenia that is associated with cancer chemotherapy.